A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Nigel H. Russell, Charlotte S. Wilhelm-Benartzi et al.|Blood Advances|2023Cited by 53